GLP-1 Weight-Loss Drugs Have Big Cons, Even If Serious Problems Are Rare
| Author | Ariana Eunjung Cha and Daniel Wu (The Washington Post) |
|---|---|
| Published | November 16, 2026 |
| Format | Article |
| Original | Read the original |
GLP-1 drugs are safe and effective for most of the millions taking them, but at that scale rare and sometimes devastating complications are surfacing, and the lawsuits now ask how much evidence of a rare risk should require a warning.
GLP-1 Weight-Loss Drugs Have Big Cons, Even If Serious Problems Are Rare
Summary
The piece opens on Todd Engel, 63, of Columbia, Maryland, who lost the sight in one eye four months after starting Ozempic for diabetes, kept taking it because nobody connected the two, then lost the other eye. He is one of thousands of patients suing Novo Nordisk and Eli Lilly for failure to warn. Both companies say the drugs are safe and the suits are without merit. The article then walks through what research currently says, category by category. Most of the reported harm is gastrointestinal, where gallstones are the clearest risk (46% relative increase, small in absolute terms) and gastroparesis is linked but unquantified. Reproductive effects run in both directions (abnormal bleeding signals in FDA reports, but restored ovulation in a small PMOS study). Nutrition and bone are a growing worry (hair loss, an 11% higher fragility-fracture risk in older diabetics). The cancer data is reassuring so far despite the rodent-based thyroid box warning. Psychiatric effects are mostly anecdotal, and one large observational study even found lower depression and anxiety risk. The eye story is the sharpest: no broad eye-safety problem, but a rare optic-nerve “eye stroke” (NAION) where a veterans study found roughly double the risk. Europe called it causal last year, and the FDA ordered a new label warning only last week. The closing question is regulatory: when tens of millions take a relatively new drug, how much evidence of a rare catastrophe is enough to warn?
Key claims
- Engel started Ozempic for diabetes and four months later woke unable to see from his right eye; months later he lost the left. He is legally blind, can no longer drive, and left his job operating heavy equipment. He is among thousands suing Novo Nordisk and Eli Lilly over inadequate warnings.
- The drug classes: Novo’s Ozempic and Wegovy are semaglutide (a synthetic GLP-1); Lilly’s Mounjaro and Zepbound are tirzepatide, which also targets the GIP pathway. Pills and triple-agonist drugs are next.
- Gastrointestinal: most label side effects are minor and temporary (nausea, diarrhea, constipation). An August review found 13 published gastroparesis cases, mostly semaglutide. Bowel obstruction raised early alarms but a large analysis found no overall increase. A review of 55 trials covering 106,395 people found a 46% increase in gallstones, small in absolute risk. Pancreatitis stays on US labels without a clear trial signal.
- Reproductive: a July Obstetrics & Gynecology study of FDA adverse-event reports found disproportionate reports of heavy or between-period bleeding among semaglutide users. A separate July study of 96 women with PMOS found more than half of non-ovulating participants began ovulating after six months of semaglutide. Sexual-function evidence is mixed and may reflect weight loss rather than the drug.
- Nutrition and bone: a 2025 review found six papers describing deficiencies (vitamin D, iron, calcium). A University of Pennsylvania study of 12,000 adults with Type 2 diabetes associated GLP-1s with higher (still low) hair-loss risk. A study of more than 46,000 older adults with diabetes found an 11% higher risk of fragility fractures versus other diabetes drugs.
- Cancer: the boxed thyroid C-cell tumor warning comes from rodent studies. A December 2025 Annals of Internal Medicine analysis of 48 placebo-controlled trials (94,245 people) found probably little or no effect on thyroid, pancreatic, breast or kidney cancer; trials are testing whether GLP-1s slow cancer.
- Psychiatric: online reports of anhedonia (“meh”), anxiety and mood swings are thin as science. A Lancet Psychiatry study of about 95,500 people with diabetes or obesity plus depression or anxiety found semaglutide users had lower risk of worsening symptoms, substance use and self-harm (observational only). The EMA began reviewing self-harm data in 2023.
- Eyes: a 2026 study of 5.5 million people associated GLP-1 use with less macular degeneration, and a 2025 JAMA Ophthalmology review of 78 trials found no overall rise in diabetic retinopathy. But for NAION, a March study of 102,361 US veterans found roughly twice the risk versus another common diabetes drug. Novo cites an April analysis of 90,000+ trial participants finding no association.
- Regulators split on timing. European regulators ruled last year that semaglutide causes NAION (“very rare”) and told patients to stop if it is confirmed; Canada, Britain and Australia added warnings. The FDA ordered new NAION labeling the week before publication, after more than a year of study. Engel’s attorney, Jonathan Orent of Motley Rice, says the delay left patients uninformed.
Notable quotes
“If anyone had told me there’s a possibility that this could happen, there is just no way that I would ever take that medication,” Engel said.
But as the lawsuits move through the courts, they are putting a difficult question at the center of the GLP-1 revolution: When millions of people are taking relatively new drugs, how much evidence of a rare but devastating risk is enough to require a warning?
As better data have accumulated, some of the scariest early signals have strengthened, while others have weakened.
“Patients think about this as a weight-loss drug, but you don’t just impact fat tissue,” Horneff said. “You impact muscle mass and certainly bone … as well.”
“This is not just a side effect, right? This is a life-altering catastrophe,” he said.
Skrbkova said that semaglutide, the GLP-1 used in Novo Nordisk medications Ozempic and Wegovy, has a “well-established safety profile” and that the lawsuits filed against Novo Nordisk are “without merit.”
“I wake up in the dark,” he said, “and I go to sleep in the dark.”
How it connects
- GLP-1: the concept page so far covers GLP-1 demand as a business story (the MEDVI telehealth case). This is the safety side of the same boom, the cost of a drug taken at population scale.
- Novo Nordisk and Eli Lilly: the two manufacturers named as defendants.
- The regulatory-timing thread (Europe ruling causal a year before the FDA labels) is a concrete case for Precautionary Principle arguments in either direction.